- Tags: retina
Research
AOA report analyzes ocular risks of GLP-1RAs
Released during the 2025 Optometry’s Meeting, this comprehensive rundown dives into potential rare ophthalmic side effects associated with use—and offers clinical care recommendations.
Research
Earlier diabetes diagnosis may lead to worsening DR progression
Study identifies mechanisms for the potential protective effect of later diabetes diagnosis on DR severity.
Research
Study identifies risk factors for myopic macular degeneration progression
Axial elongation was shown to be a key risk factor for progression, among others.
Business
Amaros secures Series A financing for AI ophthalmic evidence platform
Financing will support adoption and commercialization of the EvidenceEngine to accelerate clinical trial enrollment and generate real-world evidence on retinal disease.
Research
GLP-1 drug users twice as likely to develop nAMD
New research findings also report risk was 3 times as high among diabetic patients with the longest exposure to GLP-1 RAs.
Pipeline
FDA clears Ocugen for phase 2/3 trial on Stargardt gene therapy
IND approval enables continued clinical evaluation of OCU410ST, a modifier gene therapy with a favorable safety and tolerability profile; plans include a 2027 BLA submission.
Research
Study ties magnesium to reduced RVO risk
Sufficient magnesium intake significantly reduced risk of RVO, particularly in three key subgroups.
Research
Does silicone oil cause macular edema post-RRD surgery?
Study identifies two key factors that may significantly increase the risk for macular edema development.
Pipeline
ViGeneron rebrands as VeonGen Therapeutics with new FDA designation
German-based genetic medicine company also receives a Rare Pediatric Disease Designation for its Sargardt disease gene therapy candidate.
Pipeline
Opus Genetics reports positive phase 3 data for phentolamine 0.75%
Topline findings indicate the gene therapy achieved a ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity versus placebo.
Pipeline
FDA grants Rare Pediatric Disease designation to Stargardt gene therapy
OCU410ST could receive a priority review voucher if approved; company plans to initiate a phase 2/3 trial in coming weeks—along with a BLA filing in 2027.
Business
Therini Bio raises nearly $40M to study DME and Alzheimer's immunotherapeutics
Funding to support two trials on fibrin-targeting immunotherapies targeting vascular dysfunction-induced neuroinflammation in severe retinal and neurological diseases.
Products
FDA approves Genentech's Susvimo for DR
First sustained-release delivery system of ranibizumab earns third indication, with injections needed just once every 9 months.
Pipeline
Atsena releases favorable LIGHTHOUSE trial data on XLRS gene therapy
Positive findings from 1-year post-treatment show meaningful improvements on visual function measurements, with foveal schisis closure observed in 67% of patients.
Research
New alliance seeks a shift in healthcare via AI-based oculomics
Healthcare leader-led consortium Alliance for Healthcare from the Eye calls for a proactive healthcare approach, with a focus on prescreenings for ocular and systemic health.
Research
How safe are iPSC-based RPE strip transplants for patients with RPE degeneration?
First clinical report of allogeneic iPSC-derived RPE strip transplantation demonstrated success in all three patients.
Products
Zeiss debuts new research data platform for integrated workflows
Company’s cloud-based solution uses AI technology to integrate accessible clinical and research data into clinicians’ daily routines.
Research
LumiThera Valeda system extension trial data expands dry AMD vision improvements
Presented at ARVO, new findings support earlier initiation and extended vision benefits of Valeda Light Delivery System out to 4.5 years.
Pipeline
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.
Research